Corporate Profile and Investors’ Information

Relmada Therapeutics is a clinical-stage biotechnology company developing differentiated therapies in oncology and central nervous system disorders.

The Company is advancing a focused pipeline of high-value assets supported by strong scientific rationale, clinical validation, and clearly defined regulatory pathways.

Pipeline Overview
NDV-01 is a sustained-release intravesical formulation of gemcitabine and docetaxel (Gem/Doce) for non-muscle invasive bladder cancer (NMIBC). In an ongoing Phase 2 study, NDV-01 has produced durable complete responses with no ≥ Grade 3 treatment-related adverse events. The program is advancing into the Phase 3 RESCUE registrational program across two independent approval pathways.

Sepranolone is a neurosteroid that targets compulsivity-related disorders through modulation of GABA_A receptor activity and is advancing toward a Phase 2 trial in Prader-Willi syndrome.

Strategy
Relmada advances its pipeline through disciplined clinical execution against defined regulatory milestones, with an emphasis on:

• Durable efficacy, favorable safety, and ease of administration
• Development pathways that are clear, efficient, and aligned with regulators
• Broad clinical adoption across large, well-defined patient populations

Relmada also evaluates additional opportunities aligned with this strategy, including differentiated therapies with strong clinical and commercial potential.

Financial Position
As of March 31, 2026, Relmada had $234.0 million in cash, cash equivalents, and short-term investments, expected to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program.

Company Overview
Founded in 2004 and headquartered in Coral Gables, Florida, Relmada Therapeutics is building a pipeline of therapies designed to deliver meaningful outcomes for patients and long-term value for shareholders.